Repros Therapeutics

Repros Therapeutics — Investor Presentation (September 2014)

35 slides from Repros Therapeutics's investor presentation, Sep 22, 2014

  1. Slide 1: Androxal: A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism

    Androxal ® A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism

  2. Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discu ssi on) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to var ious risks, uncer

  3. Slide 3: Hypogonadism Background: Normal HPT Axis

    Hypogonadism Background Normal Hypothalamus - Pituitary - Testes (HPT) Axis A. Normal secretion of LH and FSH B. Normal stimulation of testes C. Results in normal testosterone levels and sperm production Seftel A. Male hypogonadism . Part II: etiology, pathophysiology , and diagnosis. Int J Impot Re

  4. Slide 4: Hypogonadism Background: Overview

    Hypogonadism Background • Hypogonadism is a condition in which a male is unable to produce sufficient testosterone (T) . • A man is considered to be clinically hypogonadal if his morning testosterone is < 300 ng / dL (normal range 300 - 1040 ng / dL ). • In a recent study, hypogonadism was estimated

  5. Slide 5: Hypogonadism Background: Primary Hypogonadism

    Hypogonadism Background • The less frequent type is primary , which is typically a result of a genetic defect, trauma or viral infections such as mumps. • This type of disorder is easily diagnosed by assessing both testosterone and the pituitary hormone that drives testicular synthesis of testostero

  6. Slide 6: Hypogonadism Background: Secondary Hypogonadism

    Hypogonadism Background • The more common dysfunction is secondary hypogonadism (85 - 95% of hypogonadal men). • This dysfunction is characterized by low testosterone and low/low normal LH and is a result of the pituitary not responding to the low T state by secreting more LH to drive T synthesis. •

  7. Slide 7: Categorizing Gonadal Status by Testosterone and LH in EMAS

    Categorizing Gonadal Status by Testosterone (T) and LH in the European Male Ageing Study (EMAS) : A General Population Observational Cohort Study Thresholds for abnormal: <Total T 10.5 nmol /L (300 ng/ dL ) and >LH 9.4 U/L (Tajar et al J Clin Endocrinol Metab 2010 95:1810) 0 20 40 60 80 LH (U/L) 0 1

  8. Slide 8: Prevalence, Group Sizes and Hormonal Distribution in Diagnostic Categories

    ​ ​ ​ Prevalence, Group Sizes and Hormonal Distribution in 4 Different Biochemical Diagnostic Categories In the European Male Ageing Study (EMAS) Thresholds for abnormal: Total T <10.5 nmol /L and >LH 9.4 U/L <10.5 nmol /L >9.4 U/L ​ (Tajar et al 2010) Area of circles represents individual group siz

  9. Slide 9: Greater Effects of BMI on Reproductive Hormone Levels in EMAS

    Wu et al. JCEM 2008 Greater Effects of BMI ( cf to Age) on Reproductive Hormone Levels in EMAS - Indicating Secondary Hypogonadism in Obesity (n = 3210)

  10. Slide 10: Two Separate Tracks of Hypogonadism

    Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Two Separate Tracks of Hypogonadism 1. Secondary hypogonadism associated with ob

  11. Slide 11: Secondary Hypogonadism at Baseline

    Secondary Hypogonadism at Baseline Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** *** * Poor morning erection Sexual thoughts Erectile dysfunction Low vigorous activity Unable to bend Slow walking speed 0 2 4 6 * * Adjusted Relativ

  12. Slide 12: Primary Hypogonadism at Baseline

    Primary Hypogonadism at Baseline Poor morning erection Sexual thoughts Erectile dysfunction Low vigorous activity Unable to bend Slow walking speed 0 2 4 6 Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** * ** *p <0.05 **p< 0.01 ***p

  13. Slide 13: Weight Effect on T Production in the Secondary Hypogonadal Male

    • A man’s weight affects his T level more than his age. • Obese men, at even a young age, experience obesity - related Low T. • Weight loss significantly improves T levels in the secondary hypogonadal male. • The secondary hypogonadal male has functional but under - stimulated testes due to obesity

  14. Slide 14: The Average American Male at All Ages Was Overweight in 2000

    The Average American Male at All Ages Was Overweight in 2000 Overweight BMI > 25 (6’ 190# male BMI=25.8) Obese BMI > 30 (6’ 230# male BMI =31.2) In 2010 there were ~90 million men in the US between the ages of 20 and 65 32% are obese

  15. Slide 15: Hormone Changes Related to % Weight Loss/Gain

    Hormone Changes (Rise/Fall) are Related to % Weight Loss/Gain (Data adjusted for age , centre, changes in smoking status, alcohol consumption co - morbidities & physical activity) n = 2395, *p<0.05, **p<0.01 % Weight loss Weight gain % 0 * ** * * * * * * ** ** ** ** * Camacho et al. European Journal

  16. Slide 16: Age & BMI of Subjects in Early Repros Androxal Studies

    Age & BMI of Subjects in Early Repros Androxal Studies Study IND # of Subjects Mean Age Mean BMI ZN - 018 65,396 52 51.2 31.95 ZA - 003 65,396 194 52.6 32.4 ZA - 202 104,921 116 57.3 33.5 ZA - 203 65,396 108 50.7 32.0 ZA - 204 65,396 60 53.1 31.8

  17. Slide 17: BMI Distribution in Study of Secondary Hypogonadism ZA-003

    BMI Distribution in Study of Secondary Hypogonadism, Repros: ZA - 003 (% of Subjects) 0 10 20 30 40 50 60 70 80 90 100 Underweight <18.5 Normal 18.5-24.9 Overweight 25-29.9 Obese>30 Weight Classification of Subjects Enrolled in ZA - 003 (n=204) Screening Criteria: T<300 ng/dL

  18. Slide 18: Androxal Improves Pituitary-Testes Signaling

    Androxal Improves Pituitary - Testes Signaling Testosterone Replacement Suppresses Pituitary Responsiveness and Testicular Function p - value < 0.0001

  19. Slide 19: % of Subjects with FSH Below Lower Limit of Normal After 3 Months

    % of Subjects with FSH Below the Lower Limit of Normal and Below the Lower Limit of Detection (0.3 mIU/ml) after 3 months ZA - 003 “Completer” Analysis

  20. Slide 20: Head to Head Comparison of Androxal to Testim and Placebo, Study ZA-203

    Head to Head Comparison of Two Doses of Androxal to Testim and Placebo, Study ZA - 203 An approved T gel significantly suppresses LH and FSH in a clinically relevant manner and suppresses sperm concentration to near severe oligospermia (median sperm concentration 6.2 million/mL) after only three mon

  21. Slide 21: Testosterone Baseline Data Consistent with Inclusion/Exclusion Criteria

    ZA - 304 & 305 Testosterone Baseline Data Consistent with Study Inclusion/Exclusion Criteria ZA - 305 Baseline Morning T (fully enrolled, n=127) Mean Age: 47 Mean BMI: 33.4 Morning T (ng/ dL ) Mean 216.2 Median 214.0 Standard Deviation 54.1 (Minimum, Maximum) (79.0,299.0) ZA - 304 Baseline Morning T

  22. Slide 22: Sperm Baseline Data Consistent with Inclusion/Exclusion Criteria

    ZA - 304 & 305 Sperm Baseline Data Consistent with Study Inclusion/Exclusion Criteria Mean: 78 million/mL, Median: 61.3 million/mL Minimum: 19 million/mL (1 subject <20) Mean: 90.8 million/mL, Median: 62.6 million/mL Minimum: 16.9 million/mL (4 subjects <20)

  23. Slide 23: Initial Screening Findings for Age ≤60, BMI >25 Category

    Initial Screening Findings for ZA - 304 & 305 Age ≤ 60, BMI > 25 Category Number of Men Age Mean ( StDev ) T ng/ dL ** Mean ( StDev ) BMI Mean ( StDev ) Total Screened 642 47.5 (8.6) 267 (83.6) 33.3 (4.6) Randomized 256 47.3 (8.3) 237 (43.8) 33.4 (4.4) Screen Failed 386 BMI>42 2 48 (5.7) - - Eye Exa

  24. Slide 24: Overweight Men Exhibit Lower Than Normal T Compared to Aged Matched Controls

    Overweight Men Exhibit Lower Than Normal T Compared to Aged Matched Controls

  25. Slide 25: Findings: LH and FSH P values, Androgel vs Baseline and Androxal

    ZA - 305 Findings LH and FSH P values @ 16 Weeks Androgel vs Baseline and Androxal p< 0.0001

  26. Slide 26: Findings: One Week Post Dosing

    ZA - 305 Findings One Week Post Dosing Androgel vs Baseline p= 0.0004 Androgel vs Androxal p< 0.0001

  27. Slide 27: Findings: Baseline vs End of Study

    305 Findings Baseline vs End of Study Androgel vs Baseline p= 0.0007 Androgel vs Androxal p= 0.0003

  28. Slide 28: Androgel Shift in Sperm Concentration

    ZA - 305 Androgel Shift in Sperm Concentration Mean: 75.1 million/mL, Median: 64.5 million/mL Minimum: 22.9 million/mL Mean: 75.1 million/mL, Median: 30.5 million/mL Minimum: 0 million/mL

  29. Slide 29: Androxal Shift in Sperm Concentration

    ZA - 305 Androxal Shift in Sperm Concentration Mean: 79 million/mL, Median: 60.9 million/mL Minimum: 19.6 million/mL Mean: 88.6 million/mL, Median: 68.2 million/mL Minimum : 9.4 million/mL

  30. Slide 30: ZA-305 Findings

    ZA-305 Findings % of Subjects Exhibiting < 10° Sperm/mL 25 P=0.0028 20 Placebo ug = Topical T 10 Enclomiphene 5 (0) % of Subjects <10 million Sperm/mL

  31. Slide 31: Influence of Prior Testosterone

    Influence of Prior Testosterone ZA - 300, 6 month study

  32. Slide 32: Androxal Safety

    Androxal Safety • Generally well tolerated at all doses – > 1500 men exposed – > 900 men for 6 months – > 150 men for 12 months – > 700 patient years of exposure • No serious drug related CV events or dose dependent events • Adverse events consistent with increasing T – No exposure of T outside the

  33. Slide 33: Clinical Implications

    Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Clinical Implications • Secondary hypogonadism is closely associated with obesit

  34. Slide 34: Upcoming Androxal Related Events

    Upcoming Androxal Related Events • FDA AdCom Meeting 9/17/14 • Anticipated Release of 304 Data Imminent • NYC Analyst Day Morning of Halloween • Submit Androxal NDA Around Year - end ‘14

  35. Slide 35: Financial Summary

    Financial Summary • Cash and equivalents (as of 8/31/14, unaudited) $55.5 M • Cash runway: Through 2016* – Anticipate Androxal approved and launched • Current shares outstanding: 24.0 M shares – Warrants Outstanding – Series A – 314,614 (purchased in unit deal @ $2.45); Series B – 429,704 @ $2.49 ex

Repros Therapeutics — Investor Presentation (September 2014) on 6ix